BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to HEp-2 cell line is 58
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 1 | 29228308 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by IF staining and qRT-PCR | NA | 0.48 | 1 | 25104726 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | SP assay followed by Western Blotting and FACs | NA | 0.48 | 1 | 29228308 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by RT-PCR | NA | 0.48 | 1 | 26021266 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | FACs followed by Migration assay | NA | 0.48 | 1 | 30210931 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | 5-Fluorouracil | FACs followed by SFA and CFA | NA | 0.48 | 1 | 27380877 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | FACs followed by SFA and CFA | NA | 0.48 | 1 | 27380877 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Docetaxel | FACs followed by SFA and CFA | NA | 0.48 | 1 | 27380877 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5461 | 29228308 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 26021266 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.6448 | 29228308 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.48 | 0.6448 | 27380877 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.48 | 0.6448 | 27380877 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.48 | 0.6448 | 27380877 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.6448 | 26021266 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.7582 | 29228308 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | SP assay followed by Western Blotting | NA | 0.48 | 0.7582 | 29228308 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.48 | 0.7582 | 27380877 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.48 | 0.7582 | 27380877 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.48 | 0.7582 | 27380877 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.7582 | 26021266 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | FACs followed by Migration assay | NA | 0.48 | 0.7582 | 30210931 |
| RXRA | 10477 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.0021 | 29228308 |
| RXRA | 10477 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | Western Blotting | NA | 0.48 | 0.0021 | 29228308 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5695 | 29228308 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | Western Blotting followed by CFA | NA | 0.48 | 0.5695 | 34837170 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.48 | 0.5695 | 27380877 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.48 | 0.5695 | 27380877 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.48 | 0.5695 | 27380877 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5695 | 26021266 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | SP assay followed by Western Blotting | NA | 0.28 | 0.1739 | 29228308 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.1739 | 25104726 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.28 | 0.1739 | 27380877 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.28 | 0.1739 | 27380877 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.28 | 0.1739 | 27380877 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | SP assay followed by Western Blotting | NA | 0.28 | 0.684 | 29228308 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.684 | 25104726 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | 5-Fluorouracil | FACs followed by SFA and CFA | NA | 0.28 | 0.684 | 27380877 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | FACs followed by SFA and CFA | NA | 0.28 | 0.684 | 27380877 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Docetaxel | FACs followed by SFA and CFA | NA | 0.28 | 0.684 | 27380877 |
| CTNNB1 | 2514 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 25104726 |
| ABCB1 | 40 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0604 | 27380877 |
| ABCB1 | 40 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0604 | 27380877 |
| ABCB1 | 40 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0604 | 27380877 |
| ABCC4 | 55 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 25104726 |
| BIRC5 | 593 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0053 | 27380877 |
| BIRC5 | 593 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0053 | 27380877 |
| BIRC5 | 593 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0053 | 27380877 |
| CCND1 | 1582 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0201 | 25104726 |
| CD24 | 1645 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.456 | 25104726 |
| NES | 7756 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0573 | 26021266 |
| NNMT | 7861 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0053 | 26021266 |
| NOTCH1 | 7881 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0477 | 27380877 |
| NOTCH1 | 7881 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0477 | 27380877 |
| NOTCH1 | 7881 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0477 | 27380877 |
| SNAI1 | 11128 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0212 | 25104726 |
| TWIST1 | 12428 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0191 | 25104726 |
| KIT | 6342 | LTM | Head and Neck Cancer | Carcinoma | HEp-2 | NA | FACs followed by Migration assay | NA | 0.12 | 0.018 | 30210931 |